Dr. Anthony Fauci, who was quadruple vaccination, said he is experiencing a “very poor” COVID rebound after being treated with Pfizer’s antiviral drug Paxlovid.
The 81-year-old White House chief medical adviser revealed his health struggles while speaking remotely at the Foreign Policy Global Health Forum on Tuesday.
The country’s leading infectious disease specialist tested positive for COVID-19 on June 15 and was initially experiencing mild symptoms, according to a statement issued at the time by the National Institutes of Health.
When his condition got worse, he began a five-day course of Paxlovid, which was granted an emergency use authorization by the Food and Drug Administration in December 2021, to treat high-risk COVID patients in an effort to prevent hospitalization went. and deaths.
Fauci said Tuesday that after recovering from his initial bout with the coronavirus, he tested negative for three days, but then tested positive again on the fourth day, the San Francisco Chronicle reported.
“And then for the next day or so, I started feeling really bad, a lot worse than before,” Fauci said. “So I went back on PaxLovid and right now I’m on day four of my five-day course.”
The scientist said he is feeling better now but “not completely without symptoms.”
In April, the Biden administration announced it was expanding the availability of Paxlovid, touting it as “one of the most effective treatments in our nation’s medicine cabinet.”
A month later, the US Centers for Disease Control and Prevention issued a warning about a COVID-19 rebound following Paxlovid treatment.
The agency said some patients who were prescribed a course of Paxlovid experienced a recurrence of COVID symptoms or tested positive for the disease between 2 and 8 days after their initial recovery.
The CDC suggested that “a brief return of symptoms may be part of a natural history of (COVID-19) infection in some individuals, independent of treatment with paxlovid and regardless of vaccination status.”
There have been no reports of serious illness linked to rebound cases, the statement said.
According to a new study from the University of California San Diego School of Medicine, the relapse of Covid-19 following PaxLovid treatment was probably due to inadequate exposure to the drug.
Because the infected cells were not getting enough drug to stop all viral replication.
The study authors suggested that this may be due to paxlovid being metabolized more quickly in some patients, or that the drug needed to be delivered over a longer treatment period.